Google
ALDX 株価分析 — ALDEYRA THE (Healthcare >> Biotechnology)
ALDX に関するよくある質問
ALDXのROE（自己資本利益率）は？
ALDEYRA THEのROEは-64.92%です。
ALDXの配当利回りは？
ALDEYRA THEの配当利回りは0.00%です。
ALDXの品質スコア（Quality Score）は？
当社のAIはALDXの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ALDXは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ALDXはどのセクターに属しますか？
ALDEYRA THEはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
ALDX AI Analysis Summary
Our AI summary for ALDX: ALDEYRA THE (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -64.92%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.54
Price
-0.06
(-3.75%)
Day Change
|
|
|---|
ALDX, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.54 |
| PBV / Sector |
2.29 / 5.20
|
| Earning Per Share | -0.44 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
2.48 M
GREAT
|
| Average 1W Daily Value |
1.27 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:27 |
| Symbol | ALDX |
| Name | ALDEYRA THE |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 60.32 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 96.51 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 131 Hartwell Avenue, Lexington, MA, United States, 02421
Phone: 781 761 4904
Website: https://www.aldeyra.com
Sector: Healthcare >> Biotechnology
Description: Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
